Loading
The one second-line CAR-T trial that failed. Its result is best explained by how long the cells took to make and what patients received while they waited.
An international phase 3 trial in patients whose aggressive B-cell lymphoma was refractory to, or progressed within 12 months of, first-line therapy. 322 patients were randomised to tisagenlecleucel with optional bridging therapy or to salvage chemotherapy and autologous haematopoietic stem-cell transplantation, with crossover allowed if a defined event occurred at or after the week 12 assessment.
Median event-free survival was 3.0 months in both groups (hazard ratio 1.07, 95 per cent confidence interval 0.82 to 1.40, p = 0.61), and response occurred in 46.3 per cent against 42.5 per cent. 95.7 per cent of the tisagenlecleucel group received the product and 32.5 per cent of the standard-care group received an autologous transplant. The median time from leukapheresis to infusion was 52 days, and 25.9 per cent of the tisagenlecleucel group had lymphoma progression by week 6 against 13.8 per cent of the standard-care group. Baseline imbalances favoured the standard-care group: 24.1 against 16.9 per cent had high-grade lymphoma and 65.4 against 57.5 per cent an International Prognostic Index of 2 or more. Ten patients in the tisagenlecleucel group and 13 in the standard-care group died from adverse events.
The reason second-line CAR-T is offered with axicabtagene ciloleucel or lisocabtagene maraleucel rather than tisagenlecleucel. The trial is also the strongest evidence in the field that the interval between apheresis and infusion, and what is given during it, is part of the treatment rather than logistics around it.
TRANSFORM confirmed ZUMA-7's conclusion with a different CD19 CAR-T and a more permissive design that allowed bridging chemotherapy, making the results closer to real-world practice. Liso-cel's low toxicity makes it attractive for older or frailer patients and for outpatient delivery. Together the two trials made CAR-T the standard second-line therapy for early-relapsing aggressive lymphoma.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
JULIET, with ZUMA-1, showed that CAR-T could rescue a substantial minority of adults with chemotherapy-refractory lymphoma and that complete responders often stay in remission. The lower toxicity of a 4-1BB construct and the option of bridging therapy made it usable in a broader population. The high drop-out between enrolment and infusion remains a lesson about turnaround time.
Shares BELINDA, TRANSFORM, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET and the tag lymphoma-evidence.
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, TRANSFORM, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, Manufacturing cost and time for living and radioactive medicines and the tag lymphoma-evidence.
Shares The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting, Tisagenlecleucel, Manufacturing cost and time for living and radioactive medicines, CD19 and the tag lymphoma-evidence.
Shares Tisagenlecleucel, Manufacturing cost and time for living and radioactive medicines, CD19, Novartis and the tag lymphoma-evidence.
Shares International Prognostic Index (IPI), Failures are hidden, Trial design, endpoints and cost, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares International Prognostic Index (IPI), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, New England Journal of Medicine, Diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares Failures are hidden, Trial design, endpoints and cost, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma-evidence.
Shares International Prognostic Index (IPI), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag lymphoma-evidence.